EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Magnetic Resonance Imaging Findings and Prostate‐Specific Antigen Density‐Based Risk Stratification for Deferring a Separate Preoperative Biopsy in Candidates for Holmium Laser Enucleation of the Prostate

Taku Mitome, Hibiki Hirose, Nanaho Demizu, Mei Tokumoto, Shinichi Takebe, Tomoharu Morikawa, Ryota Morinaga, Shuko Yoneyama, Akitoshi Takizawa

International Journal of Urology · 2026-11 · 33 (11)

DOI: 10.1111/iju.70694 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objectives To evaluate whether a separate preoperative prostate biopsy can be deferred using magnetic resonance imaging (MRI) and prostate‐specific antigen density (PSAD) in candidates for holmium laser enucleation of the prostate (HoLEP). Methods We retrospectively analyzed 625 patients who underwent HoLEP. In the high prostate‐specific antigen (PSA) cohort (≥ 4.0 ng/mL, n = 455), the diagnostic performance of PSAD was evaluated. In patients without a prior biopsy within 1 year who underwent preoperative MRI ( n = 126), candidates for biopsy deferral (MRI‐negative and PSAD < 0.20 ng/mL/mL, n = 95) were assessed. Clinically significant prostate cancer (csPCa) detection rates and histologically validated negative predictive values (NPVs) were determined using simultaneous peripheral zone (PZ) biopsy. Results Multivariable analysis identified PSAD ≥ 0.20 ng/mL/mL as an independent predictor of csPCa (odds ratio: 3.80, 95% confidence interval [CI]: 1.35–10.64, p = 0.011). In patients without a prior biopsy within 1 year ( n = 343), PSAD < 0.20 ng/mL/mL achieved a specificity of 85.9% and a biopsy deferral rate of 84.8%. Among 126 MRI‐evaluated patients, the combined criteria (MRI‐negative and PSAD < 0.20 ng/mL/mL) yielded a sensitivity of 83.3%, specificity of 78.3%, an NPV of 98.9% (94/95), and a biopsy deferral rate of 75.4% (95/126). The histologically validated NPV obtained via simultaneous PZ biopsy ( n = 77) was 98.7% (76/77). Conclusions Combining negative MRI and PSAD < 0.20 ng/mL/mL demonstrated a high NPV for csPCa and may allow the deferral of separate preoperative biopsies in selected patients with large‐volume benign prostatic hyperplasia (BPH).

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →